Cost effectiveness analysis in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 4, Issue 4, 2005, Pages 211-212

  Doran, Chris ^a   Vos, Theo ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; ECONOMIC EVALUATION; EDITORIAL; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HOME CARE; HOSPITAL CARE; HUMAN; INTERPERSONAL COMMUNICATION; LUNG FIBROSIS; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NATIONAL HEALTH SERVICE; PHYSICIAN; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES;

EID: 29544447080     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2005.09.006     Document Type: Editorial

References (6)

1. J. Thornton R.A. Elliot M.P. Tully Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: Comparing hospital and home care J Cyst Fibros 4 2005 239-247 (this issue). doi:10.1016/jcf.08.003
2. M.R. Gold J.E. Siegel L.B. Russell M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
3. M. Drummond B. O'Brien G. Stoddart G. Torrance Methods for the economic evaluation of health care programmes 1987 Oxford University Press Oxford
4. National Institute for Clinical Excellence A guide for manufacturers and sponsors: Contributing to a technical appraisal 2004 NICE London
5. National Institute for Clinical Excellence Guide to the methods of technology appraisal 2004 NICE London
6. D. Liew J. McNeil A. Peeters S.S. Lim T. Vos Epidemiological modelling (including economic modelling) and its role in preventive drug therapy MJA 177 2002 364-367